PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC today announced the peer-reviewed publication of data from the completed ReSTORE phase 3 global clinical trial evaluating REZZAYO ® ...
This presentation will give an update about easing the administrative burden on the lab to assess compliance with CLSI/FDA breakpoints. Topics addressed included FDA 510(k) approvals, the VITEK® V9.04 ...
Why mismatched resistance thresholds between CLSI and EUCAST could be masking the true scale of antimicrobial resistance in the environment. How can global standardization fix this problem? Study: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results